Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chaperonin containing TCP1 subunit 6 pseudogene 3 (CCT6P3) is annotated as a pseudogene homologous to the CCT6 subunit, one of the eight subunits that compose the heterooligomeric molecular chaperonin complex known as chaperonin containing TCP1 (CCT; also called TRiC). Unlike the protein-coding gene CCT6A, which participates in the folding of cytoskeletal proteins and plays diverse roles in cell cycle and cancer biology, CCT6P3 does not encode a functional protein product and is thus not itself a therapeutic target, enzyme, receptor, or transporter. Its biological function—if any—has not been elucidated, and it is not associated with known drug interactions, biomarker roles, or disease mechanisms. As a pseudogene, CCT6P3 is generally not considered a valid therapeutic target and is functionally distinct from its protein-coding relatives. Any reference to it as a drug target, biomarker, or disease-related entity would be incorrect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chaperonin containing TCP1 subunit 6 pseudogene 3 (CCT6P3).